Aura Paris

At Aura Paris, clinical research in Genetic Phenomena focuses on inherited kidney disorders, especially APOL1 Kidney Disease and APOL1-mediated Proteinuric Kidney Disease. These studies are designed to assess new treatment options and better understand how targeted therapies may help protect kidney function.

• Evaluating the safety and effectiveness of a new therapy for APOL1-mediated Proteinuric Kidney Disease
• Studying treatment approaches for adults and children affected by APOL1 Kidney Disease
• Testing whether targeted care can improve outcomes in proteinuric kidney disease

These trials reflect a strong interest in precision medicine for kidney conditions linked to genetic risk, with a focus on improving long-term renal health.

Research in Cardiovascular Diseases at this site examines serious heart-related risks in people with advanced kidney disease, including atherosclerotic cardiovascular disease and atrial fibrillation in the setting of Chronic Kidney Disease stage 5. The studies aim to improve stroke prevention and reduce cardiovascular complications in patients receiving dialysis or living with severe renal impairment.

• Assessing whether a blood-thinning treatment can lower stroke risk in people with atrial fibrillation and advanced kidney disease
• Exploring ways to reduce atherosclerotic cardiovascular disease in patients with end-stage kidney disease
• Evaluating treatment safety in people with CKD stage 5 who may also be on dialysis

The Dialyse department is contributing to research that connects kidney failure with major cardiovascular outcomes, an important area for patient safety and quality of care.

Clinical trials in Musculoskeletal Diseases are addressing painful inflammatory conditions, particularly gout attacks in people with advanced kidney disease, including those on dialysis or after kidney transplantation. The goal is to compare treatment options and improve symptom control in patients who have limited medication choices because of reduced kidney function.

• Comparing therapies for gout flare treatment in patients with chronic kidney disease
• Studying better ways to manage inflammation during acute gout attacks
• Evaluating treatment effectiveness in people with kidney failure and painful joint disease

By focusing on inflammation-related pain in complex kidney patients, this research aims to support safer and more effective care.

Several trials at Aura Paris involve people with end-stage kidney disease undergoing maintenance dialysis. These studies look at inflammatory markers and broader treatment outcomes, with the aim of improving health management in patients living with advanced renal failure.

• Testing whether treatment can lower inflammation in dialysis patients
• Evaluating the impact of new therapy on cardiovascular risk in ESKD
• Studying treatment options for adults with severe kidney disease receiving dialysis

This area of research is especially relevant for patients with long-term renal failure, where controlling inflammation and related complications may improve overall outcomes.